Company news
Kura Oncology, Inc. news in 2025
Kura Oncology, Inc.'s news releases, calls and decks from 2025, newest first.
Kura Oncology and Kyowa Kirin Report Combination Data for KOMZIFTI™ (Ziftomenib) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory AML
December 7, 2025
Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI®) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia
December 2, 2025
First U.S. Commercial Sale of KOMZIFTI™ Triggers $135 Million Milestone Payment to Kura Oncology Under Collaboration and License Agreement with Kyowa Kirin
December 1, 2025
KOMZIFTI™ (ziftomenib) Added to National Comprehensive Cancer Network® (NCCN) Guidelines for Acute Myeloid Leukemia (AML)
November 24, 2025
Kura Oncology and Kyowa Kirin Announce FDA Approval of KOMZIFTI™ (ziftomenib), the First and Only Once-Daily Targeted Therapy for Adults with Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia
November 12, 2025
Kura Oncology to Participate in Upcoming Investor Conference
November 11, 2025
Kura Oncology Reports Third Quarter 2025 Financial Results
November 3, 2025
Kura Oncology Receives Second $30 Million Development Milestone Payment in AML Menin Inhibitor Program With Kyowa Kirin
November 2, 2025
Kura Oncology and Kyowa Kirin Announce Presentations of Ziftomenib Ven/Aza Combination Data in Frontline and Relapsed/Refractory NPM1-m or KMT2A-r Acute Myeloid Leukemia at 2025 ASH Annual Meeting
November 2, 2025
Kura Oncology to Report Third Quarter 2025 Financial Results
October 27, 2025
Kura Oncology Receives $30 Million Development Milestone Payment in Ziftomenib AML Program with Kyowa Kirin
October 23, 2025
Kura Oncology Announces Preliminary Data from Its Farnesyl Transferase Inhibitor (FTI) Programs at the 2025 European Society for Medical Oncology (ESMO) Congress
October 17, 2025
Kura Oncology and Kyowa Kirin Launch Clinical Trial Evaluating Dual Inhibition of NPM1 and FLT3 Mutations in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)
September 30, 2025
Kura Oncology and Kyowa Kirin Announce First Patient Dosed in Pivotal Phase 3 KOMET-017 Trial of Ziftomenib for Frontline Acute Myeloid Leukemia (AML)
September 28, 2025
Kura Oncology and Kyowa Kirin Announce Publication of Pivotal Ziftomenib Data in Relapsed/Refractory NPM1-Mutated AML in the Journal of Clinical Oncology
September 24, 2025
Kura Oncology Highlights Preclinical Data Demonstrating Potential of Farnesyl Transferase Inhibitors to Overcome Drug Resistance in Combination with Key Targeted Therapies Across Multiple Tumor Types
September 15, 2025
Kura Oncology to Host Virtual Investor and Analyst Events on Farnesyl Transferase Inhibitor Program
September 2, 2025
Kura Oncology to Participate in Three Upcoming Investor Conferences
August 27, 2025
Kura Oncology Reports Second Quarter 2025 Financial Results
August 6, 2025
OMass Therapeutics Appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee
August 6, 2025
Kura Oncology to Report Second Quarter 2025 Financial Results
July 30, 2025
Kura Oncology and Kyowa Kirin Report Positive Updated Combination Data for Ziftomenib in Newly Diagnosed AML at 2025 European Hematology Association Congress
June 11, 2025
Kura Oncology and Kyowa Kirin Report Positive Pivotal Ziftomenib Monotherapy Data at 2025 ASCO Annual Meeting
June 1, 2025
Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutant AML
May 31, 2025
Kura Oncology and Kyowa Kirin Announce Pivotal Monotherapy Data for Ziftomenib in Oral Presentation at the 2025 ASCO Annual Meeting
May 21, 2025
Kura Oncology and Kyowa Kirin Announce Combination Data for Ziftomenib in Oral Presentation at the 2025 European Hematology Association (EHA) Congress
May 13, 2025
Kura Oncology to Participate in Bank of America Securities Healthcare Conference
May 5, 2025
Kura Oncology Reports First Quarter 2025 Financial Results
April 30, 2025
Kura Oncology Announces First Patients Dosed in Phase 1 Combination Trial of Ziftomenib for the Treatment of Advanced GIST
April 27, 2025
Kura Oncology to Report First Quarter 2025 Financial Results
April 23, 2025
Kura Oncology and Kyowa Kirin Announce Submission of New Drug Application for Ziftomenib to FDA
April 7, 2025
Kura Oncology to Participate in Stifel Targeted Oncology Forum
March 31, 2025
Kura Oncology Announces Preclinical Data for KO-2806 Selected for Oral Presentation at the 2025 AACR Annual Meeting
March 25, 2025
Kura Oncology Reports Fourth Quarter and Full Year 2024 Financial Results
February 25, 2025
Kura Oncology to Report Fourth Quarter and Full Year 2024 Financial Results
February 18, 2025
Kura Oncology and Kyowa Kirin Announce Positive Ziftomenib Monotherapy Registrational Trial and Positive FDA Feedback for Upcoming Frontline Combination Trial Designs
February 4, 2025
Kura Oncology Announces Senior Executive Promotions
January 5, 2025
Calls in 2025
Decks in 2025
- ASH 2025
Conference · 14 slides · Dec 24, 2025
- Technical Presentation (December 2025)
Technical · 14 slides · December 2025
- RAS-Targeted Drug Development Summit 2025
Conference · 21 slides · Sep 18, 2025
- Investor Day (June 2025)
Investor day · 33 slides · Jun 18, 2025
- 2025 ASCO Analyst and Investor Event
Conference · 30 slides · Jun 3, 2025
- Q4 2024 Earnings Presentation
Earnings · 66 slides · Feb 26, 2025
- Corporate Update (February 2025)
Corporate update · 20 slides · Feb 5, 2025
- Technical Presentation (2025)
Technical · 17 slides · 2025
- ASCO 2025
Conference · 14 slides · 2025
- Technical Presentation (2025)
Technical · 15 slides · 2025
- ASH 2025
Conference · 14 slides · 2025